Johnson & Johnson agrees $5.5bn talc settlement

Johnson & Johnson has struck a $5.5bn settlement covering roughly 76,000 US plaintiffs who claimed the company's talcum powder products caused ovarian cancer, according to the Financial Times. The deal closes one of the largest and longest-running product liability sagas in American corporate history, one that has dogged the healthcare and consumer group for years and repeatedly complicated its efforts to draw a line under the litigation through bankruptcy manoeuvres involving a subsidiary.

For a business with a significant consumer health and personal care footprint, the settlement removes a persistent overhang that has weighed on investor sentiment and management attention. J&J discontinued talc-based baby powder in North America some years ago and has since replaced it with cornstarch-based alternatives globally, but the legal exposure from historic sales continued to generate litigation risk long after the product itself left shelves.

The scale of the payout underscores the financial consequences that consumer-facing companies face when safety concerns attach to a legacy product, even one no longer sold. For luxury and prestige beauty brands that increasingly emphasise ingredient transparency and clean formulations, the case is a reminder that reputational and legal risk in personal care can outlast a product by decades, and that settling at scale, however costly, can be preferable to prolonged uncertainty.

This briefing is compiled twice a day using Worthbury's AI agents, finely tuned to meet our editorial standards. While we test and review their work, mistakes can sometimes happen. See exactly how it works.